Page 85 - Read Online

Page 18 of 22 Guerriero et al. Hepatoma Res 2019;5:6 I http://dx.doi.org/10.20517/2394-5079.2018.108

J Infect Dis 2018;67:92-7.
16. Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, et al. Elevated levels of circulating cell-free DNA in the blood of patients with
hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 2006;26:4713-9.
17. Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, et al. Circulating cell-free DNA as a predictive marker for distant metastasis of
hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 2007;97:1399-403.
18. Piciocchi M, Cardin R, Vitale A, Vanin V, Giacomin A, et al. Circulating free DNA in the progression of liver damage to hepatocellular
carcinoma. Hepatol Int 2013;7:1050-7.
19. Park S, Lee EJ, Rim CH, Seong J. Plasma cell-free DNA as a predictive marker after radiotherapy for hepatocellular carcinoma.
Yonsei Med J 2018;59:470-9.
20. Zhang C, Li J, Huang T, Duan S, Dai D, et al. Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma. Oncotarget
2016;7:81255-67.
21. Huang ZH, Hu Y, Hua D, Wu YY, Song MX, et al. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and
prognosis of hepatocellular carcinoma. Exp Mol Pathol 2011;91:702-7.
22. Hua D, Hu Y, Wu YY, Cheng ZH, Yu J, et al. Quantitative methylation analysis of multiple genes using methylation-sensitive
restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol 2011;91:455-60.
23. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular
carcinoma patients. Clin Cancer Res 2000;6:3516-21.
24. Wei L, Huang Y, Zhao R, Zhang J, Liu Q, et al. Detection of promoter methylation status of suppressor of cytokine signaling 3
(SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases. Clin Exp Med 2018;18:79-87.
25. Holmila R, Sklias A, Muller DC, Degli Esposti D, Guilloreau P, et al. Targeted deep sequencing of plasma circulating cell-free DNA
reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma. PLoS One 2017;12:e0174265.
26. Marchio A, Amougou Atsama M, Béré A, Komas NP, Noah Noah D, et al. Droplet digital PCR detects high rate of TP53 R249S
mutants in cell-free DNA of middle African patients with hepatocellular carcinoma. Clin Exp Med 2018;18:421-31.
27. Labgaa I, Villacorta-Martin C, D’Avola D, Craig AJ, von Felden J, et al. A pilot study of ultra-deep targeted sequencing of plasma
DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 2018;37:3740-52.
28. Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using
droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer 2016;7:1907-14.
29. Ikeda S, Lim JS, Kurzrock R. Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular
carcinoma: implications for targeted therapeutics. Mol Cancer Ther 2018;17:1114-22.
30. Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, et al. A phase II study of the efficacy and safety of the combination therapy of the MEK
inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin Cancer Res
2014;20:5976-85.
31. Lim HY, Merle P, Weiss KH, Yau T, Ross P, et al. Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-
mutated hepatocellular carcinoma. Clin Cancer Res 2018;24:4650-61.
32. Cai ZX, Chen G, Zeng YY, Dong XQ, Lin MJ, et al. Circulating tumor DNA profiling reveals clonal evolution and real-time disease
progression in advanced hepatocellular carcinoma. Int J Cancer 2017;141:977-85.
33. Negrini M, Ferracin M, Sabbioni S, Croce CM. MicroRNAs in human cancer: from research to therapy. J Cell Sci 2007;120:1833-40.
34. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. Detection of elevated levels of tumour-associated microRNAs in
serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
35. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
36. Thomson JM, Parker JS, Hammond SM. Microarray analysis of miRNA gene expression. Methods Enzymol 2007;427:107-22.
37.Miotto E, Saccenti E, Lupini L, Callegari E, Negrini M, et al. Quantification of circulating miRNAs by droplet digital PCR: comparison
of EvaGreen- and TaqMan-based chemistries. Cancer Epidemiol Biomarkers Prev 2014;23:2638-42.
38. Wojcicka A, Swierniak M, Kornasiewicz O, Gierlikowski W, Maciag M, et al. Next generation sequencing reveals microRNA isoforms
in liver cirrhosis and hepatocellular carcinoma. Int J Biochem Cell Biol 2014;53:208-17.
39. Dingle TC, Sedlak RH, Cook L, Jerome KR. Tolerance of droplet-digital PCR vs real-time quantitative PCR to inhibitory substances.
Clin Chem 2013;59:1670-2.
40. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, et al. Absolute quantification by droplet digital PCR versus analog
real-time PCR. Nat Methods 2013;10:1003-5.
41. Mangolini A, Ferracin M, Zanzi MV, Saccenti E, Ebnaof SO, et al. Diagnostic and prognostic microRNAs in the serum of breast
cancer patients measured by droplet digital PCR. Biomark Res 2015;3:12.
42. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, et al. Circulating micro-RNA expression profiles in early stage
nonsmall cell lung cancer. Int J Cancer 2012;130:1378-86.
43. Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as
novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep 2014;41:4513-9.
44. Oksuz Z, Serin MS, Kaplan E, Dogen A, Tezcan S, et al. Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p
could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma. Mol Biol Rep 2015;42:713-20.
45. Qi P, Cheng SQ, Wang H, Li N, Chen YF, et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients
with chronic hepatitis B virus infection. PLoS One 2011;6:e28486.
46. Xu J, Wu C, Che X, Wang L, Yu D, et al. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular
carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42.
47. Ge W, Yu DC, Li QG, Chen X, Zhang CY, et al. Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular
carcinoma and their clinical significances. Clin Lab 2014;60:427-34.